Sarepta (SRPT) shared updates from its clinical programs focused on limb-girdle muscular dystrophy subtypes 2C/R5, 2D/R3, and 2E/R4. Following ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates ...

William Blair analyst Sami Corwin maintained a Hold rating on Applied Therapeutics (APLT – Research Report) today. The company’s shares closed ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal ...

We recently published a list of 11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts. In this article, we are ...

Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...

Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Sarepta (SRPT) to $182 from $196 and keeps an Overweight rating on the ...

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), with a ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Alnylam Pharma (ALNY – Research Report), with a price ...

In a report released today, Gil Blum from Needham maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), with a price ...

It was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession ...